Providing more testing choices does not increase colorectal cancer screening rates

August 30, 2019

Offering patients the choice between home screening or in-office colonoscopy does not increase participation in colorectal cancer screening, according to a new Penn Medicine study. However, the framing of choice did impact patient decision-making, as the proportion of colonoscopies -- the gold standard for colorectal cancer screening -- fell when the home screening option was presented as an available option. This study was published in JAMA Network Open.

"As clinicians, we should think carefully about the choices that we offer to patients: While they're well-meaning and seemingly more patient-centered, choices may actually be overwhelming and could impede decision-making," said the study's lead author, Shivan Mehta, MD, MBA, associate chief innovation officer at Penn Medicine and an assistant professor of Medicine. "It is important for us to simplify choices as much as possible, but also think about how we frame them."

One in three people in the United States are not up-to-date on their screening for colorectal cancer, the second deadliest cancer in the United States, so doctors and researchers like Mehta and his team are working on ways to make tests more widespread and/or easier to complete. For this study, they explored whether offering fecal immunochemical testing (FIT), a stool test that can be completed at home and mailed to a lab as an alternative choice to colonoscopies would boost screening completion. FIT kits are often viewed as more convenient, but they need to be completed yearly to keep patients up to date. Colonoscopies are more comprehensive, allowing for the removal of potentially harmful tissues, and only need to be performed once a decade.

"We know from behavioral science that we all tend to overweigh present-time risks as compared to future benefits," Mehta explained. "In the short term, it's easier to get stool testing done, but the need to do it yearly presents more opportunities for a patient to get behind on their screening. Conversely, colonoscopies are more challenging in the short term, but they keep patients up-to-date longer."

A group of 438 patients overdue for screening were equally separated into three different study arms. Each received a letter from their primary care physician about the benefits of screening. The first group also received a phone number to call to schedule a colonoscopy. If they didn't schedule within in four weeks, they got a follow-up letter with the same information.

Patients in the second group received a number they could call for scheduling a colonoscopy, in addition to the letter. But if they, too, didn't schedule one within four weeks, they were then mailed a reminder letter along with a FIT kit (with instructions and a stamped envelope with which to return it).

Finally, patients in the third arm received the colonoscopy scheduling number and the FIT kit immediately. In four weeks, without either screening completed, they would then get a letter with information both about colonoscopy scheduling and the FIT kit.

The study showed that colonoscopy popularity fell as FIT kits became more readily available, with colonoscopies being used in 90 percent of the completed screenings in the first arm, 52 percent in the second, and just 38 percent in the third. However, overall screening rates did not vary significantly, with each group having roughly the same numbers.

"One interpretation of our results is that any of these strategies can be deployed by health systems with reasonable effectiveness," Mehta said.

Moving forward, Mehta said he would like to examine the long-term effects of these choices with more participants, as there may be small but significant differences in response rate. In particular, he'd like to examine variations of the sequential choice option -- the second arm that offered colonoscopy information before mailing a FIT kit four weeks later.

"Specifically, we would like to explore how long we should wait before we offer stool testing when patients do not participate in colonoscopy," Mehta said. "This may offer a clue as to whether there is a better timing option that might increase screening rates while accounting for the need to repeat stool testing annually."
-end-
This study was funded by the Penn Roybal Center through the Institute of Aging (grant number P30AG034546) and the National Cancer Institute of the National Institutes of Health (K08CA234326 and R01CA213645).

Other authors include Vikranth Induru, MD; David Santos; Catherine Reitz, MPH; Timothy McAuliffe; Charles Orellana, MD; Kevin G. Volpp, MD, PhD; David A. Asch, MD, MBA; Chyke A. Doubeni, MD, MPH.

University of Pennsylvania School of Medicine

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.